Research programme: cannabinoid CB2 receptor agonists - BTG
Latest Information Update: 21 Aug 2019
Price :
$50 *
At a glance
- Originator BTG
- Class Cannabinoids
- Mechanism of Action Cannabinoid receptor CB2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Multiple sclerosis; Neuropathic pain; Pain
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 05 Mar 2004 This programme is available for licensing in Europe, North America, and Japan (http://www.btgplc.com)
- 05 Mar 2004 Preclinical trials in Pain in USA (unspecified route)